间变淋巴瘤激酶阳性非小细胞肺癌靶向治疗现状被引量：4

导出

摘要肺癌是全球死亡率最高的恶性肿瘤,5年生存率约为18％.非小细胞肺癌（non-small cell lung cancer,NSCLC）约占肺癌的85％,约70％的患者确诊时已为晚期[1].目前晚期NSCLC的化疗疗效已进入平台期,而靶向治疗为突破这一瓶颈提供了新的解决方案.表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKI）的广泛应用成功开启了NSCLC靶向治疗时代.2007年间变淋巴瘤激酶（anaplastic lymphoma kinase,ALK）融合基因的发现是NSCLC靶向治疗的另一里程碑.克唑替尼是首个被开发的小分子ALK激酶抑制剂,2011年获得美国食品和药物管理局（FDA）批准用于治疗晚期ALK阳性NSCLC.

作者张宁宁韩晓红石远凯

机构地区中国医学科学院北京协和医学院肿瘤医院肿瘤内科抗肿瘤分子靶向药物临床研究北京市重点实验室

出处《中华结核和呼吸杂志》 CAS CSCD 北大核心 2015年第10期773-777,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases

基金国家自然科学基金（81372384,81472752）国家高技术研究发展计划（863计划,2011AA02A110）国家重大新药创制科技重大专项（2012ZX09303012）抗肿瘤分子靶向药物临床研究北京市重点实验室2012年度阶梯计划项目（Z121102009212055）北京市科技计划（D141100000214005,D141100000214003）高等学校博士学科点专项科研基金（20131106130004）

关键词酪氨酸激酶抑制剂非小细胞肺癌靶向治疗淋巴瘤晚期NSCLC 阳性间变美国食品和药物管理局

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献49

1Vijayvergia N, Mehra R. Clinical challenges in targetinganaplastic lymphoma kinase in advanced non-small cell lungcancer [ J ]. Cancer Chemother Pharmacol, 2014, 74(3):437-446.
2Shiota M,Fujimoto J, Semba T, et al. Hyperphosphorylation of anovel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1lymphoma cell line, AMS3 [ J]. Oncogene, 1994,9(6):1567-1574.
3Soda M,Choi YL,Enomoto M, et al. Identification of thetransforming EML4-ALK fusion gene in non-small-cell lung cancer[J], Nature, 2007, 448(7153) :561-566.
4Sasaki T, Rodig SJ, Chirieac LR, et al. The biology andtreatment of EML4-ALK non-small cell lung cancer [ J ]. Eur JCancer, 2010, 46(10):1773-1780.
5Liu YT, Shi YK, Hao XZ, et al. Analysis of clinicopathologicalfeatures of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients withadvanced non-small-cell lung cancer[ J]. Thorac Cancer, 2014,5(3):255-260.
6Han XH, Zhang NN, Ma L, et al. Immunohistochemistry reliablydetects ALK rearrangements in patients with advanced non-small-cell lung cancer[ J]. Virchows Arch, 2013 , 463(4) :583-591.
7赵菁,周建娅,陈茜,丁伟,周建英.特异性抗体检测对非小细胞肺癌小标本中间变性淋巴瘤激酶融合基因重排的价值[J].中华结核和呼吸杂志,2014,37(3):212-213. 被引量：1
8Zhang NN, Liu YT, Ma L,et al. The molecular detection andclinical significance of ALK rearrangement in selected advancednon-small cell lung cancer: ALK expression provides insights intoALK targeted therapy[ J]. PLoS One, 2014,9(1) :e84501.
9Takeuchi K,Soda M,Togashi Y, et al. RET, ROS1 and ALKfusions in lung cancer[ J]. Nat Med, 2012,18(3) :378-381.
10Kim H, Park .,Kim YJ, et al. ALK rearrangement in a puresquamous cell carcinoma : the challenge of detection of ALKrearrangement[ J]. Virchows Arch, 2013 , 462(5) :597-599.

二级参考文献50

1Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation[ J]. Lung Cancer, 2012, 77:460-463.
2Wong DW, Leurtg EL, Wong SK, et aL A novel KIF5B-ALK variant in nonsmall cell lung cancer [ J ]. Cancer, 2011, 117 : 2709-2718.
3Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448:561-566.
4Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer [ J ]. Cell, 2007,131:1190-1203.
5ShawAT, Varghese AM, Solomon BJ, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lun cancer [ J ]. Ann Oncol. 2013.24 : 59-66.
6郝捷,赵平,陈万青.2011年全国肿瘤登记年报[J].北京:军事医学科学出版社,2012:1.
7Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH [ J ]. J Thorac Oncol, 2011, 6:459-465.
8Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm mi proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing[ J]. Arch Pathol Lab Med, 2012,136:796-803.
9Mari M, Lucian RC, Kenny Law, et al. A novel, highly sensitive antibody allows for routine detection of ALK -rearranged lung adenocarcinomas by standard immunohistochemistry [ J ]. Clin Cancer Res, 2010, 16 : 1561-1570.
10Yi ES, Boland JM, Maleszewski JJ, et al, Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH [ J]. J Thorac Oncol, 2011, 6:459-465.